Successful and long‑term response to trastuzumab plus paclitaxel combination therapy in human epidermal growth factor receptor 2‑positive extramammary Paget's disease: A case report and review of the literature
Affiliations: Department of Comprehensive Cancer Therapy, Shinshu University School of Medicine, Matsumoto, Nagano 390‑8621, Japan, Department of Surgery, Nagano Red Cross Hospital, Nagano, Nagano 380‑0928, Japan
- Published online on: September 19, 2017 https://doi.org/10.3892/mco.2017.1422
- Pages: 763-766
Copyright: © Ichiyama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...
This article is mentioned in:
A 58‑year‑old woman with a histologically confirmed diagnosis of vulvar extramammary Paget's disease (EMPD) was referred to our hospital due to locally advanced and relapsed EMPD. The patient had undergone surgical resection three times for relapsed vulvar EMPD over a period of 12 years, but developed locally advanced and unresectable EMPD. As pathological examination indicated that the lesion was positive for human epidermal growth factor receptor 2 (HER2) on immunohistochemical staining, the patient was treated with trastuzumab plus paclitaxel. The primary tumor mass and lymph node metastasis regressed successfully with combined trastuzumab and paclitaxel therapy, and the disease has been stable for >2 years after the initiation of treatment. These observations suggest that HER2 status must be determined in patients with advanced and/or metastatic extramammary Paget's disease and therapy with HER2 inhibitors should be considered as an option for the treatment of HER2‑positive EMPD.